News Center

Discover all of the trending news of the Ipsen Group


150 results

Rare diseases

A Life in a Day of an FOP person: from Empathy to Understand...

You can never truly understand what it’s like to live with an ultra-rare condition unless…

Ipsen anti-corruption system certification renewed in 2022

In December 2021, Ipsen received ISO 37001 certification for its anti-corruption management systems by Eurocompliance,…

Financial information

A word from CEO David Loew

"Our growth platforms have delivered strong sales performance, reflecting improving commercial execution and the strength…

Business

Ipsen becomes a founding sponsor of the second Biolabs innov...

Ipsen announces that it becomes a founding sponsor of the second Biolabs innovation brain hub…

The Ixcellence Network®: celebrating 10 years of progress in...

By Hamzah Baig, Senior Global Medical Affairs Director for Neuroscience at Ipsen   Continuing medical…

‘A Life in a Day’: the realities of living with FOP

By Abbie Pound, Culture and Engagement Director, Patient Centricity Champion, CSR Champion. UK & Ireland…

Ipsen receives SBTi approval for climate targets

In October 2021, Ipsen pledged ambitious action on climate change. Today, we announce that Ipsen’s…

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition…

ILC 2022: Let’s talk PBC

The International Liver Congress (ILC)1 provides a key opportunity for us to meet and…

A message from CEO David Loew

Hear what CEO David Loew has to say about our H1 2022 results. [video width="800"…

Business

How to transform the medical organization in specialty care ...

By Steven Hildemann, MD, PhD, EVP, Chiel Medical Officer Medical affairs play a central role…

Ipsen publishes strong Q1 2022 results

Ipsen is pleased to announce a strong first-quarter total-sales performance. Total sales, excluding Consumer HealthCare,…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022